The KD Pharma Group has acquired a 51% stake in Trigal Pharma

BIOGGIO, SWITZERLAND – October 4, 2021 – The KD Pharma Group has acquired a 51% stake in Trigal Pharma, a company specialized in clinical research, development and marketing of medical cannabinoids, such as Cannabidiol (CBD) in a highly-purified form.

“Trigal has successfully and profitably grown by being a first mover in the API market for cannabidiol (“CBD”), which is a natural fit with the KD Pharma Group,” said Oscar Groet, CEO of the KD Pharma Group.  “KD Pharma is a technology leader in lipid-based APIs, so adding cannabinoid leadership from Trigal into the KD Pharma family will help accelerate growth for both companies in this dynamic area.”

“We are pleased to form this strategic partnership with KD Pharma,” said Dr. Eberhard Pirich MD and CEO of Trigal Pharma, “because we have a shared vision that the market will demand more highly purified cannabinoids made under pharma GMP conditions in the future.”

The KD Pharma Group manufactures extracts and cannabinoid isolates at its facilities in Germany using its broad portfolio of lipid technologies, including novel technology for the extraction, concentration and isolation of cannabinoids. Trigal Pharma manufactures and distributes CBD API through the magistral preparations channel in Austria and Germany, including a partnership with a large Austrian pharmacy. The KD Pharma Group’s goal is to build the market leader in medical cannabinoids, a market that is largely untapped and has significant growth potential due to the pipeline of research in conditions ranging from neurological and psychotic disorders, treatment of substance use disorders and addiction, chronic pain conditions to cardiovascular disease and cancer.

Trigal Pharma will form an advisory board comprising of directors appointed by both companies immediately following the close of the transaction.  Other terms of the transaction were not disclosed.

About Trigal Pharma

Trigal Pharma is a pharmaceutical company, founded 2011 with more than 15 years of practical experience in clinical research and development, regulatory affairs and marketing of medical cannabinoids, particularly Cannabidiol. Since 2015 Cannabidiol capsules of different strengths as well as liquids for magisterial preparations have been developed in a very successful R&D cooperation with an Austrian pharmacy. Since more than four years in accordance with GMP standards CBD capsules have been produced for clinical trials in Australia and Europe, as well. In summary Trigal Pharma understands its role as a service company bringing scientific and marketing expertise in different sectors to globally operating manufacturers and producers of natural CBD and other cannabinoids.

About the KD Pharma Group SA

The KD Pharma Group is a CDMO that develops products in the pharmaceutical and nutraceutical space. It is also the worldwide leading producer of API for Omega-3 pharmaceuticals and has built a similar market-leading position in Omega-3 nutraceuticals, formulation and encapsulation services, with over 500 employees and a presence in the UK, Norway, Germany, Switzerland and the US. The KD Pharma Group employs state-of-the-art technology which is protected by numerous patents. Visit www.kdpharmagroup.com to learn more.

Pressemitteilungen

capiton acquires a stake in Solvis, a sustainable heating pioneer, backing the members of the management team which remain significant shareholders in the company. Solvis is headquartered in Braunschweig, Germany. The company was founded in 1982 and retains its operations in a factory which has been inaugurated as the first zero-emission-facility in Germany in 2002. […]

capiton acquires the majority stake in Kutterer Mauer AG, backing one of the founders, Mr. Mauer in continuing the growth story of the company. Mr. Mauer as well as other management members invest alongside capiton. Kutterer Mauer AG is a globally operating manufacturer of caps and closure solutions with >450 employees. The Group designs and […]

capiton has successfully closed a new top-up single-asset fund for its fast-growing portfolio company KD Pharma Group („KD Pharma“). This top-up fund will provide KD Pharma with the equity financing for a number of additional strategic investments, in particular add-on acquisitions as well as organic growth initiatives to transfer KD Pharma‘s unique technology and service […]

We are delighted to announce the successful acquisition of 4PICO Litho by Raith. Raith, the leading global manufacturer of precision technology for nanofabrication instrumentation, has expanded its product offering by adding direct write laser lithography systems – manufactured by 4PICO Litho – to its business strategy. In 2004 4PICO Litho, located near Eindhoven (NL) started […]

capiton acquires majority stake in Stürtz Group. Stürtz Group, headquartered in Neustadt (Wied), Germany, is a market-leading designer, producer, and marketer of automated solutions for the window production industry across the globe. The company generated approximately EUR 46 million in sales in 2020 and employs around 270 FTEs across five locations globally. Stürtz’ product portfolio […]

Dec Group acquires Extract Technology We are delighted to announce the successful acquisition of Extract Technology by Dec Group. Extract Technology is a leading provider of containment and aseptic systems for the pharmaceutical, biotech, nuclear and chemical markets. Extract is headquartered in Huddersfield (UK) with a second facility in New Lisbon (US), serving the fast-growing […]

capiton acquires majority stake in Axxence Group The management team of the Axxence Group acquires in a MBO along with capiton the leading natural aroma chemicals manufacturer from its founder, Joost van Neck. Axxence Group, headquartered in Emmerich, Germany, is a leading manufacturer and supplier of natural aroma chemicals (NACs) for the global flavour & […]

EVP Group acquires Group Korott We are delighted to announce the successful acquisition of Group Korott by EVP Group. Group Korott is a leading manufacturer and distributor of vitamins, minerals, natural cosmetics, as well as sport supplements for the Spanish consumer healthcare market. In addition to its store-brand partnering business, Korott has its own brand […]

Engelmann, with headquarters in Wiesloch, Germany, is the leading European manufacturer of smart heat meters for the sub-metering industry.

Wundex Group, with headquarters in Senden, Germany, is a leading home care provider for patients with chronic wounds. The company‘s qualified wound managers provide home care services that enable faster and more effective wound treatment and significantly reduce the workload of general care providers and physicians, backed by an integrated digital platform.

Die Cedes AG („Cedes“) mit Sitz in Landquart (Schweiz) ist ein führendes Sensortechnologie Unternehmen in der Aufzugs- und Türenindustrie. Unter Verwendung von Infrarot- und Bildverarbeitungstechnologie werden die Produkte für die Automatisierung von Aufzügen, Rolltreppen und Eingängen eingesetzt. Cedes wurde 1986 gegründet und erwirtschaftete 2019 rund CHF 55 Mio. Umsatz mit rund 320 Mitarbeitern.

Die MIP Gruppe („MIP“) ist ein international aufgestellter Hersteller und Distributor von generischen Arzneimitteln mit Schwerpunkt auf Antiinfektiva. Neben Antibiotika bietet MIP rezeptfreie Medikamente und Medizinprodukte an. Die Produkte werden größtenteils in den zwei eigenen Produktionsstandorten im Saarland, Deutschland, gefertigt. Mit ca. 400 Arzneimittelzulassungen und ca. 251 Mitarbeitern generiert MIP Umsätze i.H.v. über € 40 Mio. in 19 Ländern.